Rango de valoración compuesto · conservador HK$260–HK$280 / razonable HK$390–HK$560 / optimista HK$660–HK$705. A HK$419, Dentro del rango de valor intrínseco razonable.
A Phase III trial of sac-TMT versus chemotherapy as first-line treatment for advanced TNBC met its PFS primary endpoint.
Possible impact:May affect expectations for sac-TMT label expansion and commercial potential.
Kelun-Biotech announced 2025 annual results, highlighting multiple product launches and progress across a tiered pipeline.
Possible impact:May affect market views on revenue growth, R&D spending and pipeline execution.
Automatically summarized from public sources; for context only, not investment advice.
Descripción de la empresa próximamente.
PróximamenteEsta sección se está completando; vuelve pronto.
PróximamenteEsta sección se está completando; vuelve pronto.
Aún no hay análisis sobre este valor en tu idioma.